Xinermei, launched in July, is the third once-weekly injectable GLP-1 weight management therapy available in China after Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro. ADVERTISEMENTThe market share of weight-loss drugs in China is opaque, with firms including Innovent and Lilly not disclosing sales figures. Innovent in 2019 secured exclusive development and commercialisation rights in China for mazdutide from Lilly under undisclosed financial terms. ADVERTISEMENTUnlike Wegovy and Mounjaro, it also targets a hormone called GCG, an approach Innovent argues could have benefits for liver health. Asked for information on prescription volume for Xinermei, Wegovy and Mounjaro, he said it was related to when each drug launched.